Everygene Launches No-Cost Genetic Testing for Cardiomyopathy with Broad Clinical Labs and Mass General Brigham

CAMBRIDGE, Mass., July 23, 2025 (Everygene) — Everygene, in collaboration with Broad Clinical Labs (BCL) and the Laboratory for Molecular Medicine (LMM) at Mass General Brigham, has launched a nationwide, no-cost genetic testing program for individuals with cardiomyopathy.

 

This initiative addresses the critical gap where fewer than 2% of the over one million U.S. cardiomyopathy patients receive genetic testing, despite its potential to prevent serious outcomes like heart failure. BCL’s high-resolution blended genome-exome assay detects rare variants, while LMM provides expert interpretation of cardiomyopathy-related genes. ‘Most people with genetic cardiomyopathy are never tested,’ said Jeb Balise, Everygene’s CEO. The program includes genetic counseling and optional cascade testing for relatives.